Formycon AG (FYB.F)
| Previous close | 53.80 |
| Open | 54.00 |
| Bid | 0.00 x 30000 |
| Ask | 0.00 x 30000 |
| Day's range | 54.00 - 54.00 |
| 52-week range | 27.00 - 79.80 |
| Volume | 150 |
| Avg. volume | 617 |
| Market cap | 584.42M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.75 |
- EQS Group
Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021
DGAP-News: Formycon AG / Key word(s): Miscellaneous/Miscellaneous15.09.2021 / 08:40 The issuer is solely responsible for the content of this announcement.Press Release // September 15, 2021Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB20
- EQS Group
Formycon reports on the status of FYB207 development
DGAP-News: Formycon AG / Key word(s): Scientific publication/Study11.08.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Press Release // August 11, 2021Formycon reports on the status of FYB207 development- Efficient neutralization of SARS-CoV-2 variants-of-concern- Production for preclinical and clinical product established at fast track- Expansion of preclinical efficacy testing planned- Phase I/IIa clinical trial expected to start first half of 2022Munich -
- EQS Group
Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)
Formycon AG / Key word(s): Regulatory Admission/MiscellaneousFormycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)05-Aug-2021 / 22:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publi
